[go: up one dir, main page]

MX2015009045A - COMPOSITIONS AND METHODS TO TREAT SEVERE PAIN. - Google Patents

COMPOSITIONS AND METHODS TO TREAT SEVERE PAIN.

Info

Publication number
MX2015009045A
MX2015009045A MX2015009045A MX2015009045A MX2015009045A MX 2015009045 A MX2015009045 A MX 2015009045A MX 2015009045 A MX2015009045 A MX 2015009045A MX 2015009045 A MX2015009045 A MX 2015009045A MX 2015009045 A MX2015009045 A MX 2015009045A
Authority
MX
Mexico
Prior art keywords
methods
compositions
severe pain
treat severe
pharmaceutical compositions
Prior art date
Application number
MX2015009045A
Other languages
Spanish (es)
Inventor
John Brew
Robin Mark Bannister
George William Schlich
Original Assignee
Infirst Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infirst Healthcare Ltd filed Critical Infirst Healthcare Ltd
Publication of MX2015009045A publication Critical patent/MX2015009045A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente especificación revela composiciones farmacéuticas, métodos de preparación de dichas composiciones farmacéuticas, y métodos y usos de tratamiento de una inflamación crónica y/o una enfermedad inflamatoria en un individuo utilizando dichas composiciones farmacéuticas.The present specification discloses pharmaceutical compositions, methods of preparation of said pharmaceutical compositions, and methods and uses of treatment of a chronic inflammation and / or an inflammatory disease in an individual using said pharmaceutical compositions.

MX2015009045A 2013-01-14 2014-01-14 COMPOSITIONS AND METHODS TO TREAT SEVERE PAIN. MX2015009045A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361752356P 2013-01-14 2013-01-14
PCT/EP2014/050628 WO2014108569A1 (en) 2013-01-14 2014-01-14 Compositions and methods for treating severe pain

Publications (1)

Publication Number Publication Date
MX2015009045A true MX2015009045A (en) 2015-12-17

Family

ID=50064547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009045A MX2015009045A (en) 2013-01-14 2014-01-14 COMPOSITIONS AND METHODS TO TREAT SEVERE PAIN.

Country Status (14)

Country Link
EP (1) EP2943183A1 (en)
JP (1) JP6474732B2 (en)
KR (1) KR20150129665A (en)
CN (1) CN104968330A (en)
AU (1) AU2014204739B2 (en)
BR (1) BR112015015864B1 (en)
CA (1) CA2897874A1 (en)
HK (1) HK1217650A1 (en)
IL (1) IL239921A0 (en)
MX (1) MX2015009045A (en)
RU (1) RU2677346C2 (en)
SG (1) SG11201505245XA (en)
WO (1) WO2014108569A1 (en)
ZA (1) ZA201505005B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
WO2018027001A1 (en) * 2016-08-03 2018-02-08 Temple University-Of The Commonwealth System Of Higher Education Microencapsulation of active agents
JP7027786B2 (en) * 2017-10-12 2022-03-02 ライオン株式会社 Oral treatment for myofascial pain
WO2022207580A2 (en) 2021-03-27 2022-10-06 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics
CN116660550B (en) * 2023-06-19 2024-08-13 南通大学 Method for alleviating pain by using a DGAT2 inhibitor PF-06424439

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
CA2294033C (en) * 1997-07-29 2007-01-09 Pharmacia & Upjohn Company Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US8663692B1 (en) * 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
AU4917900A (en) * 1999-05-07 2000-11-21 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
EP1183014B1 (en) * 1999-06-14 2003-10-08 Cosmo S.p.A. Controlled release and taste masking oral pharmaceutical compositions
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
JP3763567B2 (en) * 2001-01-19 2006-04-05 株式会社資生堂 Cosmetics
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
EP1817012A2 (en) * 2004-11-24 2007-08-15 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
CA2607738A1 (en) * 2005-04-28 2006-11-02 Galenica Technology Ab Pharmaceutical dosage forms comprising a lipid phase
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2009153496A2 (en) 2008-05-26 2009-12-23 Genfit Ppar agonist compounds, preparation and uses
CN102048680B (en) * 2009-11-11 2013-05-01 河北奥星集团药业有限公司 Enteric sustained-release preparation containing zaltoprofen and preparation method thereof
CN103391768B (en) * 2011-02-04 2016-08-10 第一医疗保健有限公司 Treat chronic inflammatory disease and the compositions of inflammatory diseases and method
CN102579350B (en) * 2012-03-02 2013-04-24 海南灵康制药有限公司 Pidotimod liposome solid preparation

Also Published As

Publication number Publication date
KR20150129665A (en) 2015-11-20
WO2014108569A1 (en) 2014-07-17
BR112015015864A8 (en) 2018-01-16
IL239921A0 (en) 2015-08-31
JP6474732B2 (en) 2019-02-27
CA2897874A1 (en) 2014-07-17
SG11201505245XA (en) 2015-08-28
AU2014204739A1 (en) 2015-07-16
HK1217650A1 (en) 2017-01-20
CN104968330A (en) 2015-10-07
BR112015015864A2 (en) 2017-07-11
RU2015134136A (en) 2017-02-20
EP2943183A1 (en) 2015-11-18
RU2677346C2 (en) 2019-01-16
AU2014204739B2 (en) 2016-08-11
JP2016504401A (en) 2016-02-12
BR112015015864B1 (en) 2022-08-23
ZA201505005B (en) 2016-10-26

Similar Documents

Publication Publication Date Title
MX2015009045A (en) COMPOSITIONS AND METHODS TO TREAT SEVERE PAIN.
MX366317B (en) COMPOSITIONS AND METHODS TO TREAT CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES.
MX2015009104A (en) COMPOSITIONS IN SOLID SOLUTION AND USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES.
EP3052476A4 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
LT2986304T (en) PHARMACEUTICAL COMPOSITION, METHODS OF ADMINISTRATION AND THEIR USE
MX391858B (en) Therapeutically active compounds and their methods of use
UY35693A (en) PIRAZOLO [1,5-A] PIRIDIN-3-SUBSTITUTED CARBOXAMIDS AND THEIR USE
MX370900B (en) DERIVATIVES OF ISOCROMEN AS INHIBITORS OF PHOSPHOINOSITIDE-3 KINASES.
UY35652A (en) BENCIL-1H-PIRAZOLO [3,4-B] PIRIDINES AND ITS USE
HUE046671T2 (en) A pharmaceutical composition containing glutarimide derivatives and its use in the treatment of eosinophilic diseases
MX2018012285A (en) TREATMENT METHODS FOR COLESTIC AND FIBROTIC DISEASES.
MX2018005825A (en) MODIFIED IMMUNE CELLS AND USES OF THE SAME.
MX383944B (en) COMPOSITIONS FOR PERSONAL CARE.
WO2014153385A3 (en) Methods of treating metabolic disorders
CR20150653A (en) NEW COMPOUNDS FOR CANCER TREATMENT
BR112015029894A2 (en) solid pharmaceutical dosage form
MX375318B (en) DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLORINE KYNURENINE.
MX2016011025A (en) GRAPIPRANT COMPOSITIONS AND METHODS TO USE THE SAME.
CL2015003211A1 (en) Synergistic combination of paracetamol / celecoxib for the treatment of inflammatory pain.
MX2019009909A (en) Pharmaceutical compositions for combination therapy.
CO2018004803A2 (en) Oxa-diazaspiro compounds that have activity against pain
CL2015000778A1 (en) Synergistic oral pharmaceutical composition comprising nitazoxanide and mebendazole; Preparation process; and use to treat human parasitosis caused by protozoa and helminths.
AR130700A2 (en) GRAPIPRANT COMPOSITIONS AND METHODS OF USE
DOP2015000290A (en) BENZOXAZOLES REPLACED
AR099681A1 (en) GRAPIPRANT COMPOSITIONS AND METHODS FOR USE